Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 14, 2015 - Issue 5
Submit an article Journal homepage
535
Views
5
CrossRef citations to date
0
Altmetric
Key Paper Evaluation

Combination therapy for patients with uncontrolled type 2 diabetes mellitus: adding empagliflozin to pioglitazone or pioglitazone plus metformin

Evaluation of Kovacs CS, Seshiah V, Swallow R, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-158

Thomas BlevinsTexas Diabetes & Endocrinology, P.A, 6500 N MoPac Expwy, Building III, Suite 200, Austin, TX 78731, USA+1 512 458 8400; [email protected]
, MD
Pages 789-793 | Published online: 19 Mar 2015

Bibliography

  • CSKovacs, VSeshiah, RSwallow, et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 2014;16:147-58
  • JJNeumiller. Empagliflozin: a new sodium-glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Drugs Context 2014;3:212262
  • ALiakos, TKaragiannis, EAthanasiadou, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014;16:984-93
  • SEInzucchi, RMBergenstal, JBBuse, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9
  • AJGarber, MJAbrahamson, JIBarzilay, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract 2013;19:327-36
  • American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2015;38(Suppl):S1-93
  • MRoden, JWeng, JEilbracht, et al. EMPA-REG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013;1:208-19
  • HUHäring, LMerker, ESeewaldt-Becker, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 2014;37:1650-9
  • Boehringer Ingelheim Pharmaceuticals, Inc. Jardiance (empagliflozin) [prescribing information]. 2014. Available from: https://www.jardiance.com [Last accessed 15 December 2014]
  • MRidderstrale, KRAndersen, CZeller, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2014;2:691-700
  • RVOliva, GLBakris. Blood pressure effects of sodium-glucose co-transport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014;8:330-9

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.